Opus Genetics (IRD) said Friday that it has priced a $20 million underwritten public offering, as well as a concurrent private placement for gross proceeds of $1.5 million.
The ophthalmic biotechnology company said there will also be up to $21.4 million in additional proceeds when the warrants are exercised. The offerings are expected to close Monday.
Opus said the net proceeds will be used to fund the clinical development of its lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, as well as general corporate purposes and working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.